The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
Fatima Amanat(Icahn School of Medicine at Mount Sinai), Florian Krammer(Icahn School of Medicine at Mount Sinai), Shaza M. Sayed Ahmed(Washington University in St. Louis), Nicholas Borcherding(University of Iowa), Ali H. Ellebedy(Washington University in St. Louis), Shirin Strohmeier(Icahn School of Medicine at Mount Sinai), Willemijn F. Rijnink(Icahn School of Medicine at Mount Sinai), Julian Q. Zhou(AbCellera (Canada)), Aaron J. Schmitz(Washington University in St. Louis), Komal Srivastava(Icahn School of Medicine at Mount Sinai), Tinting Lei(Washington University in St. Louis), Harm van Bakel(Icahn School of Medicine at Mount Sinai), Hala Alshammary(Icahn School of Medicine at Mount Sinai), Sarah Zafar(Icahn School of Medicine at Mount Sinai), Ana S. Gonzalez‐Reiche(Icahn School of Medicine at Mount Sinai), Goran Bajic(Icahn School of Medicine at Mount Sinai), Jackson S. Turner(Washington University in St. Louis), Mahima Thapa(Washington University in St. Louis), Emilia Mia Sordillo(Mount Sinai Health System), Daniel C. Adelsberg(Icahn School of Medicine at Mount Sinai), Viviana Simon(Icahn School of Medicine at Mount Sinai), Juan Manuel Carreño(Icahn School of Medicine at Mount Sinai)
Cited by 44
Related Papers
Influenza
|Nature Reviews Disease Primers|2018|1.5k
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
|New England Journal of Medicine|2021|803